Navigation Links
Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
Date:4/15/2008

PRINCETON, N.J., April 15 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today interim results from two ongoing Phase 1 trials in hormone refractory prostate cancer (HRPC) demonstrating dose-dependent T-cell activation and clinical activity of ipilimumab, an investigational anti-CTLA-4 antibody. These studies were done in combination with antigen-releasing immunotherapies based on GM-CSF, a cytokine that stimulates the proliferation of white blood cells and augments immune responses, and results were presented in two separate oral presentations by investigators at the Annual Meeting of the American Association for Cancer Research (AACR), being held April 12-16, 2008 in San Diego.

"The interim results demonstrating clinical activity in these ongoing trials lend additional support to the concept of ipilimumab as part of a therapeutic regimen in treating prostate cancer," said Geoffrey M. Nichol, M.B.Ch.B., Senior Vice President of Product Development at Medarex. "We will continue to explore the prospects of ipilimumab in HRPC, and we expect further data in prostate cancer for ipilimumab monotherapy and in combination with other antigen-releasing agents at this year's ASCO conference in June."

-- "Dendritic and T cell functions in patients with metastatic

hormone-refractory prostate cancer treated with GVAX immunotherapy for

prostate cancer and ipilimumab" (Abstract #2538)

Interim data from the ongoing Phase 1 study of escalating doses of

ipilimumab in combination with the Cell Genesys, Inc. GVAX

immunotherapy for prostate cancer (an investigational agent comprised

of whole tumor cells modified to secrete GM-CSF) were presented by

Saskia JA
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
2. Medarex to Receive Milestone Payment from Amgen
3. Medarex Announces Ipilimumab Program Continues to Move Forward
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Spherix Reports Second Quarter Earnings
6. Tapestry Reports Second Quarter 2007 Results
7. Callisto Reports on Second-Quarter 2007 Milestones
8. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
9. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
10. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
11. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2008)...Trial Results Confirm Efficacy for Population Most...E, Calif., May 16 /-,Bayer ...uticals, Inc.,(Nasdaq: ONXX ) today announced tha...roved overall survival by 47.3 percent (HR=0.68;,p...on with advanced,hepatocellular carcinoma (HCC), o...
(Date:5/15/2008)... BASEL, Switzerland, May 15 /- Patien...rld,s most common cancers, can expect,further trea...erceptin(R),(trastuzumab) following new data that ... Clinical Oncology (ASCO) annual meeting in Chicag... will attend the meeting which,is the premier even...
(Date:5/15/2008)...- First in human clinical data highlight safety pr...advanced solid tumors -, BRISBANE, Calif., May 15... held biopharmaceutical company developing novel c...ing its lead PARP inhibitor, BSI-201, will,be pres...ology annual,meeting in Chicago., Findings will b...
(Date:5/15/2008)...hase II Data Presented at ASCO Showed Acceptable T...e of Grade 3 and 4 Neuropathy, WOODCLIFF LAKE, N....motherapeutic agent eribulin mesylate (E7389) demo...on of women with locally advanced or metastatic,br...r Phase II clinical,trial. The study also suggests...
Breaking Medicine Technology:Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 2Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 3Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 4Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 5Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 6New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 2New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 3New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 4New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 5New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 6BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3Genes and environment interact in first graders to predict physical but not social aggression 2145 1Genes and environment interact in first graders to predict physical but not social aggression 2145 2The Ensign Group Inc Announces the Appointment of Covey C Christensen as President of Its Flagstone Subsidiary 11233 1The Ensign Group Inc Announces the Appointment of Covey C Christensen as President of Its Flagstone Subsidiary 11233 2New funding to charge energy research at UCL and the London Centre for Nanotechnology 3094 1New funding to charge energy research at UCL and the London Centre for Nanotechnology 3094 2Celebrity Cook Paula Deen and Husband Michael Groover Bring Smithfield Foods Helping Hungry Homes 28TM 29 Tour to L A 11232 1Celebrity Cook Paula Deen and Husband Michael Groover Bring Smithfield Foods Helping Hungry Homes 28TM 29 Tour to L A 11232 2Celebrity Cook Paula Deen and Husband Michael Groover Bring Smithfield Foods Helping Hungry Homes 28TM 29 Tour to L A 11232 3
...EM, & LUND, Sweden--(BUSINESS WIRE)--May 1, 20...e Biotech AB today,announced that data from a 36-w...Phase IIb study demonstrated that an oral 0.6 mg,d...d magnetic,resonance imaging (MRI) disease activit...rated. In addition, there was a favorable,trend to...
... confirmed EDSS progression reduced by 40 percent ...7 /PRNewswire/ -- Bayer HealthCare,Pharmaceuticals...te,initiation(1) of Betaseron(R) (interferon beta-...stive of multiple sclerosis (MS),can significantly...ent as measured by the Expanded Disability Status ...
Other Medicine Technology:Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 2Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 3Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 4Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 5Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 6First of Its Kind Data Show: Immediate Treatment of Early MS,Patients with Betaseron Significantly Delayed Permanent Disability 2First of Its Kind Data Show: Immediate Treatment of Early MS,Patients with Betaseron Significantly Delayed Permanent Disability 3First of Its Kind Data Show: Immediate Treatment of Early MS,Patients with Betaseron Significantly Delayed Permanent Disability 4
(Date:5/17/2008)...t report could not establish safe-limit price as g..., May 17 (HealthDay News) -- Those inexpensive ear...y be good for your wallet but bad for your ears an... earrings sold for less than $50 by local San Fran... cause dermatitis on the earlobes and repeated exp...
(Date:5/16/2008)NEW YORK, May 16 /PRNewswire/ -- There,s more to a healthy mouth than,flashing a set of pearly whites. Here,s the scoop on America,s oral care,habits - and what it means for our overall health.,
(Date:5/16/2008)... Contract Covers More than 500 Workers, WASHINGT...0 paramedics,and emergency medical technicians in ...gton area have ratified their first-ever contract ...ese workers are now covered by a,strong contract t...ent,future," said Teamsters General President Jim ...
(Date:5/16/2008)...Small fibroids located just beneath the lining of ... the endometrial cavity after uterine artery embol...ations, according to a new study. , The study i...t an MRI examination before and after UAE. The stu...e, 33% migrated to the endometrial cavity after UA...
Breaking Medicine News(10 mins):Health News:Cheaper Earrings More Likely to Contain Nickel 2Health News:Cheaper Earrings More Likely to Contain Nickel 3
... the AMA Rural Reference Group (AMARRG), Dr David ...y Transport Minister, Warren Truss, //of enhanceme...) was a welcome piece of rare good news for rural ...igned to attract GPs to work in country areas and ...
...xperts at University of Iowa are taking efforts to...cribed only when really needed.// Salmeterol is a...on with a corticosteroid, which is inhaled. The us...iorate the asthma for a few people with that condi...
...ers have uncovered important information about how... a critical step in DNA mutation that has eluded r...rs in the August edition of the Journal of the Ame... Institute of Technology have reported uncovering ...
...e about three severe, potentially fatal genetic di...that they can rupture in pregnancy and labor or ev...a blockers, curbing exercise, proactive blood vess...be helpful, but their usefulness varies according ...
Other Medicine News:Health News:RMIF Boost a Boon for Rural Health 2Health News:Salmeterol - to be used in combination & only when required 2Health News:Salmeterol - to be used in combination & only when required 3Health News:Elusive Step In DNA Mutation Uncovered By Researchers 2Health News:Elusive Step In DNA Mutation Uncovered By Researchers 3Health News:Elusive Step In DNA Mutation Uncovered By Researchers 4Health News:Scientists Review Loeys-Dietz Syndrome in the Largest Ever Study to date 2Health News:Scientists Review Loeys-Dietz Syndrome in the Largest Ever Study to date 3
For use with 8 channel pipets.
...sign, manually adjustable dispensing head, and dis...e brings unparalleled flexibility and cost-efficie...t instrument of its kind to offer fast dispensing ...,000L). It also offers the added benefit of being ...
...atented non-contact dispensing technique that coup...valve and stage stepper motor. synQUAD dispenses a...lides, plates, or membranes. At 100 nL dispense vo...less than 10%. An 8-channel synQUAD system dispens...
The WP1000S is a shortened base version of the WellPro that is shortened 5 inches to facilitate fitting into smaller biohazard hoods.
Medicine Products: